General procedure for the synthesis of A and A-c1. by Xueqin lu (22250795)

Differentially expressed genes (DEGs)^a showing the greatest fold changes from each potato tissue: 10 with greatest increase in expression and 10 with greatest decrease in expression. by Margaret A. Carpenter (6104180)

“…<p>Differentially expressed genes (DEGs)^a showing the greatest fold changes from each potato tissue: 10 with greatest increase in expression and 10 with greatest decrease in expression.…”

Plasma cholesterol and LDL-C levels. by Xueqin lu (22250795)

¹³C NMR spectra for Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

The G215S mutation decreases packaging of N and growth in primary differentiated human bronchial cells. by Hannah C. Kubinski (21213168)

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

The level of miRNA 221 in the myocardium of MIRI mice was decreased. by Hongyu Li (1332669)

Subjects:

General procedure for the synthesis of B. by Xueqin lu (22250795)

Effects of Kylo-0603 on body weight, organ weight, and body fat content. by Xueqin lu (22250795)

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. by Xueqin lu (22250795)

Kylo-0603’s EC50 & tissue levels. by Xueqin lu (22250795)

The body weight and cholesterol levels of the mice were recorded before the administration of the drug. by Xueqin lu (22250795)

The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

¹H NMR spectra for kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

The structures of T3 and Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

Synthesis process of Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

ESI-HRMS spectra for Kylo-0603. by Xueqin lu (22250795)

“…Meanwhile, Kylo-0603 demonstrated a marked improvement in histological parameters, decreasing steatosis by up to 1.3 points (P < 0.001), inflammation by 1.8 points (P < 0.0001), and ballooning by 0.8 points (P < 0.01). …”

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. by Xueqin lu (22250795)

General procedure for the synthesis of Kylo-0603. by Xueqin lu (22250795)

Effect of Kylo-0603 drug on the reversal of steatosis and inhibition of fibrotic process in liver tissues of the MASH mouse models (F2 ~ 3), analyzed by SHG/TPEF microscopy combine... by Xueqin lu (22250795)